VIVUS (VVUS) Qsymia Prescriptions Pop Following Thanksgiving Glut (ARNA) (OREX)
Tweet Send to a FriendGet Alerts VVUS Hot Sheet
Price: $12.98 --0%
Rating Summary:
6 Buy, 6 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 20 | New: 16
Rating Summary:
6 Buy, 6 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 20 | New: 16
Trade VVUS Now!
VIVUS, Inc. (Nasdaq: VVUS) is ticking higher in early trading Monday following reports that Qsymia prescriptions rose following the Thanksgiving holiday.
According to Bloomberg Industries-compiled data, prescriptions to the weight-loss drug rose 21 percent in the week ended November 29th.
BI thinks Thanksgiving boosted overall demand, with retail prescriptions rising 19 percent sequentially. Qsymia prescriptions fell 6 percent during the week of Thanksgiving.
Shares of VIVUS are indicated 2 percent higher Monday morning. Traders are likely to keep an eye on Arena Pharma (Nasdaq: ARNA) and Orexigen (Nasdaq: OREX) following the news. Both are key players in the obesity pill game along with VIVUS.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
According to Bloomberg Industries-compiled data, prescriptions to the weight-loss drug rose 21 percent in the week ended November 29th.
BI thinks Thanksgiving boosted overall demand, with retail prescriptions rising 19 percent sequentially. Qsymia prescriptions fell 6 percent during the week of Thanksgiving.
Shares of VIVUS are indicated 2 percent higher Monday morning. Traders are likely to keep an eye on Arena Pharma (Nasdaq: ARNA) and Orexigen (Nasdaq: OREX) following the news. Both are key players in the obesity pill game along with VIVUS.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- QVT Financial Purchase $20M of Convertible Debt Issued by VIVUS (VVUS)
- Morgan Stanley Says Tesla (TSLA) 'Top Pick in U.S. Autos'
- Merck's (MRK) Suvorexant Faces Challenges at FDA
Create E-mail Alert Related Categories
Analyst Comments, FDA
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
